Stay updated on Incyte Press Releases
Sign up to get notified when there's something new on the Incyte Press Releases page.
Latest updates to the Incyte Press Releases page
- Check4 days agoChange DetectedIncyte has announced its participation in an upcoming investor conference on December 17, 2024, while the report on its third quarter financial results from October 29, 2024, has been removed.SummaryDifference13%
- Check12 days agoChange DetectedIncyte has added late-breaking data on Tafasitamab (Monjuvi®) showing improved progression-free survival for follicular lymphoma at ASH 2024, while it has been removed from the list of top employers by Science Magazine.SummaryDifference20%
- Check19 days agoChange DetectedIncyte has announced positive results from a Phase 3 trial of Retifanlimab in combination with chemotherapy for non-small cell lung cancer, while recent updates include inducement grants under Nasdaq rules, following the removal of previous announcements related to atopic dermatitis and third quarter financial results.SummaryDifference37%
- Check26 days agoChange DetectedIncyte has updated the presentation time for an upcoming investor conference and will highlight new data, including a late-breaking oral presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting.SummaryDifference32%
- Check33 days agoChange DetectedIncyte has provided an update on its early phase MRGPRX2 and MRGPRX4 programs as of November 18, 2024, while a previous announcement regarding late-breaking data presentations at the EADV 2024 Congress has been removed.SummaryDifference21%
- Check41 days agoChange DetectedIncyte has announced its upcoming presentation at an investor conference on November 14, 2024, while a previous announcement regarding a publication related to the AGAVE-201 trial has been removed.SummaryDifference17%
Stay in the know with updates to Incyte Press Releases
Enter your email address, and we'll notify you when there's something new on the Incyte Press Releases page.